SCHEMBL25072528

SCHEMBL25072528

O=C(O)c1cnc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.39
▸ P4HTM Q9NXG6 3/20 0.38
▸ CSNK2A2 P19784 1/20 0.36
▸ CSNK2A1 P68400 1/20 0.36
▸ HDAC1 Q13547 2/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC9 Q9UKV0 2/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC7 Q8WUI4 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC10 Q969S8 1/20 0.35
▸ HDAC11 Q96DB2 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ HDAC5 Q9UQL6 1/20 0.35
▸ MAPT P10636 3/20 0.33
▸ NPSR1 Q6W5P4 3/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25073308 0.85 P4HTM (0.49) PTPN11P4HTMCSNK2A2CSNK2A1HDAC1
SCHEMBL25073254 0.84 CSNK2A2 (0.46) PTPN11CSNK2A2CSNK2A1HDAC1MAPT
SCHEMBL25073028 0.80 PTPN11 (0.44) PTPN11P4HTMCSNK2A2CSNK2A1HDAC1
SCHEMBL25734826 0.80 MAPT (0.42) P4HTMMAPTNPSR1ALDH1A1KMT2A
SCHEMBL25073200 0.79 PTPN11 (0.43) PTPN11CSNK2A2CSNK2A1HDAC1HDAC3
SCHEMBL25072408 0.79 PTPN11 (0.51) PTPN11P4HTMCSNK2A2CSNK2A1MAPT
SCHEMBL25073205 0.79 HDAC1 (0.45) PTPN11CSNK2A2CSNK2A1HDAC1HDAC3
SCHEMBL25073082 0.77 PTPN11 (0.39) PTPN11CSNK2A2CSNK2A1HDAC1HDAC3
SCHEMBL25073171 0.77 ALDH1A1 (0.44) MAPTNPSR1KDM4EALDH1A1RAB9A
SCHEMBL25072757 0.77 PTPN11 (0.41) PTPN11CSNK2A2CSNK2A1HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 PTPN11 3612/4885P4HTM 507/4885CSNK2A2 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback